Glicoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment

被引：1

作者：

Bogousslavsky, J

Paciaroni, M

Gallai, V ^{[1
]}

机构：

[1] Univ Perugia, Dept Neurosci, I-06100 Perugia, Italy

[2] Univ Lausanne, CHUV, Dept Neurol, Lausanne, Switzerland

来源：

CLINICAL AND EXPERIMENTAL HYPERTENSION | 2002年 / 24卷 / 7-8期

关键词：

stroke; GP IIb/IIIa receptors; cerebral ischemia; thrombosis;

D O I：

10.1081/CEH-120015336

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The benefit of antiplatelet therapy remains unclear, although it does appear that aspirin monotherapy started within 48 hours of stroke onset may result in a modest clinical improvement. Glicoprotein (GP) IIb/IIIa antagonists are currently considered the most powerful specific inhibitors of platelet activation in acute thrombosis. Glicoprotein IIb/IIIa inhibitor therapy could merit a prominent role also in the initial management of patients with acute ischemic stroke. Abciximab may be promising in this setting and should be evaluated in further clinical trials.

引用

页码：603 / 610

页数：8

共 50 条

[1]

Adams HP, 2000, STROKE, V31, P601

[2]

Adams Jr HP, 1999, CEREBROVASC DIS, V9, P127

[3] PHARMACOKINETICS AND PHARMACODYNAMICS OF MK-383, A SELECTIVE NONPEPTIDE PLATELET GLYCOPROTEIN-IIB/IIIA RECEPTOR ANTAGONIST, IN HEALTHY-MEN [J].

BARRETT, JS ;

MURPHY, G ;

PEERLINCK, K ;

LEPELEIRE, ID ;

GOULD, RJ ;

PANEBIANCO, D ;

HAND, E ;

DECKMYN, H ;

VERMYLEN, J ;

ARNOUT, J .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (04) :377-388

[4]

Bazzino O, 1998, NEW ENGL J MED, V338, P1498

[5]

Bazzino O, 1998, NEW ENGL J MED, V338, P1488

[6]

Bednar B, 1996, CIRCULATION, V94, P571

[7] Antiplatelet therapy in acute cerebral ischemia [J].

Bednar, MM ;

Gross, CE .

STROKE, 1999, 30 (04) :887-893

[8]

Berkowitz SD, 1997, CIRCULATION, V95, P809

[9] Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes [J].

Bhatt, DL ;

Topol, EJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (12) :1549-1558

[10] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].

CALIFF, RM ;

SHADOFF, N ;

VALETT, N ;

BATES, E ;

GALEANA, A ;

KNOPF, W ;

SHAFTEL, J ;

BENDER, MJ ;

AVERSANO, T ;

RAQUENO, J ;

GURBEL, P ;

COWFER, J ;

COHEN, M ;

CROSS, P ;

BITTL, J ;

EDDINGS, K ;

TAYLOR, M ;

DEROSA, K ;

HATTEL, L ;

COOPER, L ;

ESHELMAN, B ;

FINTEL, D ;

NIEMYSKI, P ;

KLEIN, L ;

KENNEDY, H ;

THORNTON, T ;

KEREIAKES, D ;

MARTIN, L ;

ANDERSON, L ;

HIGBY, N ;

ELLIS, S ;

BREZINA, K ;

GEORGE, B ;

CHAPEKIS, A ;

SMITH, D ;

ANWAR, A ;

GERBER, TL ;

PRITCHARD, GL ;

MYLER, R ;

SHAW, R ;

MURPHY, M ;

WARD, K ;

MADIGAN, NP ;

BLANKENSHIP, J ;

HALBERT, M ;

FLANAGAN, C ;

TANNENBAUM, M ;

POLICH, M ;

STEVENSON, C ;

TCHENG, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961

← 1 2 3 4 5 →